Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model

Centessa Pharmaceuticals has launched with a first-of-its-kind model involving the merger of ten biotechs and $250m in series A backing. The new company was created through the merger of ten private biotechs, which will sit under the Centessa umbrella as subsidiaries.

Headed up by a couple of industry heavyweights, and founded by UK life sciences venture capital firm Medicxi, the stated goal is to create a new R&D model which cuts...